Nomigran100mg
Type:4 Tablets
Generic Name:Sumatriptan
Manufacturer:Ambee Pharmaceuticals Ltd.
Price:৳180.68
Indication
Migraine, Cluster headache
Administration
May be taken with or without food.
Adult Dose
Oral Migraine Adult: >18 yr: 50-100 mg repeated at 2-hr intervals if migraine recurs. Max: 200 mg/24 hr. Mild to moderate hepatic impairment: Max single dose: 50 mg. Severe hepatic impairment: Contraindicated
Child Dose
<18 years: Safety and efficacy not established
Contraindication
Not to be used prophylactically and in patients with basilar or hemiplegic or ophthalmoplegic migraine. History of MI or stroke, severe hepatic impairment, ischaemic heart disease, uncontrolled hypertension, peripheral vascular disease, hypersensitivity to sulfonamides.
Mode of Action
Sumatriptan is a selective serotonin agonist that acts at 5-HT1 receptors. It causes vasoconstriction of cranial arteries and/or inhibition of neurogenic inflammatory processes in the CNS. A small but significant delay in gastric emptying also occurs.
Precaution
Conditions predisposing to seizures, presence of coronary risk factors, cardiac arrhythmias, renal or hepatic impairment, elderly, pregnancy, lactation. Lactation: Excreted in breast milk at very low levels; minimize infant to potential exposure by avoiding breastfeeding for 8-12 hours after administration
Side Effect
>10% Injection site reaction (<86%),Paresthesia (5-14%),Dizziness (12%),Warm/hot sensation (11%) 1-10% Chest discomfort/pressure/tightness (2-5%),Jaw or neck tightness (1-5%),Diaphoresis (2%),Burning sensation (7%),Cold sensation (1%),Dysphagia,Sore throat (3%),Malaise (1%),Abdominal distress (1%) Frequency Not Defined Agitation,Cardiac arrhythmia: V-fib/V-tach (rare),Dysuria,Eye irritation,Flushing,MI and coronary artery vasospasm in patients with CAD risk factors (extremely rare),Nasal discomfort,Palpitations,Tingling,Weakness Potentially Fatal: Cardiac arrhythmias, MI.
Interaction
Concurrent use increased risk of vasospastic reaction with ergotamine and related compounds. Potentially Fatal: Increased risk of serotonin syndrome with concurrent use of SSRI, MAOIs or within 14 days of stopping MAOIs. Admin of ergotamine or related compounds within the previous 24 hr.
